Secondary analysis of a phase 3 trial in 588 patients with nonmetastatic Ewing sarcoma: 5-year local failure was 6% overall and did not differ by surgery, radiotherapy or both (5%, 8.4%, 5.6%; P=.47); tumours ≥200 mL had higher local failure (11.3% vs 3.9%).
Secondary analysisn = 588 patients
Ahmed et al. Factors Associated With Primary Site Local Therapy in Patients With Nonmetastatic Ewing Sarcoma Treated With Interval-Compressed Chemotherapy: A Report From the Children's Oncology Group